Overview
Public BiotechLSDHiring
Developing COMP360 synthetic psilocybin therapy for treatment-resistant depression. Currently in Phase 3 trials with Breakthrough Therapy designation from FDA. Headquartered in London with offices in New York.
Visit WebsiteLondon, UK
$850M
Market Cap
2016
Founded
150
Employees
34
Open Roles